rituximab
not tagged
['lymsm']
rct of observation vs rt in pmbcl with cmr after induction #17icml - 268 pts (2/3 high risk/bulky)
- 5-yr pfs 96% obs, 98% rt; os &gt;99%
- all severe cardiac aes/spms in rt arm
- so few events occurred that study was no longer powered (58 mo f/u)
can forgo rt if cmr. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈